Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

Market Cap	289M 248M 234M 213M 398M 27.38B 400M 2.77B 1.07B 14B 1.08B 1.06B 44.54B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	385M 331M 311M 284M 530M 36.49B 533M 3.69B 1.43B 18.65B 1.45B 1.41B 59.36B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.6x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
26/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
23/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
26/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

08-14	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
08-06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	31/05/2007
Linda Powers CEO	Chief Executive Officer	71	07/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	31/12/1999

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation : Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases : Northwest Biotherapeutics, Inc

Managers and Directors : Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	31/12/1997
Linda Powers CHM	Chairman	71	16/05/2007
Navid Malik BRD	Director/Board Member	57	31/03/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+2.02%	+1.26%	+41.37%	+105.18%	69.19B
ARGENX SE	-0.95%	-4.77%	+31.37%	+74.42%	62.97B
INSMED INCORPORATED	-1.11%	+2.78%	-14.86%	+375.59%	27.27B
BIONTECH SE	-4.92%	-3.22%	-3.90%	-17.87%	24.78B
WUXI BIOLOGICS (CAYMAN) INC.	-0.93%	-0.81%	+29.69%	+14.38%	25.8B
GENMAB A/S	+0.23%	-0.32%	+23.25%	-16.36%	20.11B
PHARMAESSENTIA CORPORATION	+6.04%	+7.25%	+233.25%	+383.12%	18.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.43%	-2.43%	-8.12%	+515.88%	14.88B
EXELIXIS, INC.	-2.27%	+1.37%	+53.01%	+160.83%	14.29B
Average	-0.37%	+0.74%	+42.79%	+177.24%	30.86B
Weighted average by Cap.	-0.12%	+0.11%	+37.85%	+139.89%

	2026 *	2027 *
Net sales	-	38.93M 33.48M 31.49M 28.74M 53.63M 3.69B 53.91M 373M 144M 1.89B 146M 143M 6B
Net income	-	-
Net Debt	96.08M 82.61M 77.72M 70.92M 132M 9.11B 133M 921M 356M 4.66B 361M 353M 14.82B	125M 107M 101M 92.23M 172M 11.84B 173M 1.2B 463M 6.05B 469M 459M 19.27B

End-of-day quote OTC Bulletin Board
- ^USD	-